Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Cash on Hand

<< Previous

Bullboard Posts

Next >>

Comment by MikeStockon Jan 10, 2021 12:41pm

161 Views

Post# 32263338

RE:RE:RE:Cash on Hand

I too would love for someone to buy 346, 352 and 340 and make the decision for me about how much the shares are worth and put this all to bed one great morning. Anything south of $6B CAD for the lot and I'm laughing for the rest of my life.

<< Previous

Bullboard Posts

Next >>

Cannabix advances marijuana breathalyzer tech